{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:07:17Z","timestamp":1788448037656,"version":"build-2803163510"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012659","name":"Foundation for Innovative Research Groups of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81621001"],"award-info":[{"award-number":["81621001"]}],"id":[{"id":"10.13039\/501100012659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>We aimed to establish a model that can predict refractory\/recurrent cytomegalovirus (CMV) infection after haploidentical donor (HID) hematopoietic stem cell transplantation (HSCT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Consecutive acute leukemia patients receiving HID HSCT were enrolled (n = 289). We randomly selected 60% of the entire population (n = 170) as the training cohort, and the remaining 40% comprised the validation cohort (n = 119). Patients were treated according to the protocol registered at <jats:uri>https:\/\/clinicaltrials.gov<\/jats:uri> (NCT03756675).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The model was as follows: Y = 0.0322 \u00d7 (age) \u2013 0.0696 \u00d7 (gender) + 0.5492 \u00d7 (underlying disease) + 0.0963 \u00d7 (the cumulative dose of prednisone during pre-engraftment phase) \u2013 0.0771 \u00d7 (CD34+ cell counts in graft) \u2013 1.2926. The threshold of probability was 0.5243, which helped to separate patients into high- and low-risk groups. In the low- and high-risk groups, the 100-day cumulative incidence of refractory\/recurrent CMV was 42.0% [95% confidence interval (CI), 34.7%\u201349.4%] vs. 63.7% (95% CI, 54.8%\u201372.6%) (<jats:italic>P<\/jats:italic> &amp;lt; 0.001) for total patients and was 50.5% (95% confidence interval (CI), 40.9%\u201360.1%) vs. 71.0% (95% CI, 59.5%\u201382.4%) (<jats:italic>P<\/jats:italic> = 0.024) for those with acute graft-versus-host disease. It could also predict posttransplant mortality and survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We established a comprehensive model that could predict the refractory\/recurrent CMV infection after HID HSCT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p><jats:uri>https:\/\/clinicaltrials.gov<\/jats:uri>, identifier NCT03756675.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2022.862526","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T16:20:49Z","timestamp":1648484449000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["A Predicted Model for Refractory\/Recurrent Cytomegalovirus Infection in Acute Leukemia Patients After Haploidentical Hematopoietic Stem Cell Transplantation"],"prefix":"10.3389","volume":"12","author":[{"given":"Meng-Zhu","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen-Da","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Hua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Zhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Dong","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1162\/neco.1989.1.3.312","article-title":"The Vapnik-Chervonenkis Dimension: Information Versus Complexity in Learning","volume":"1","author":"Abu-Mostafa","year":"1989","journal-title":"Neural Comput."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e275","DOI":"10.1016\/j.bbmt.2020.07.034","article-title":"Impact of Anti-CMV IgG Titers and CD34 Count Prior to Hematopoietic Stem Cell Transplantation From Alternative Donors on CMV Reactivation","volume":"26","author":"Arcuri","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3760\/cma.j.issn.0253-2727.2017.01.001","article-title":"Chinese Expert Consensus on the Diagnosis and Treatment of Aplastic Anemia (2017)","volume":"38","year":"2017","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1182\/blood.V99.8.2726","article-title":"Association of CD34 Cell Dose With Hematopoietic Recovery, Infections, and Other Outcomes After HLA-Identical Sibling Bone Marrow Transplantation","volume":"99","author":"Bittencourt","year":"2002","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1145\/76359.76371","article-title":"Learnability and the Vapnik-Chervonenkis Dimension","volume":"36","author":"Blumer","year":"1989","journal-title":"J. ACM"},{"key":"B6","volume-title":"Thomas\u2019 Hematopoietic Cell Transplantation","author":"Blume","year":"2016"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/cid\/ciy696","article-title":"Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials","volume":"68","author":"Chemaly","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jcv.2015.12.003","article-title":"Risk Factors for Cytomegalovirus DNAemia Following Haploidentical Stem Cell Transplantation and Its Association With Host Hepatitis B Virus Serostatus","volume":"75","author":"Chen","year":"2016","journal-title":"J. Clin. Virol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/bmt.2016.69","article-title":"The Patient\u2019s CMV Serological Status Affects Clinical Outcome After T-Cell Replete Haplo-HSCT and Post-Transplant Cyclophosphamide","volume":"51","author":"Crocchiolo","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"B10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/bjh.12363","article-title":"Management of Cytomegalovirus Infection in Haemopoietic Stem Cell Transplantation","volume":"162","author":"Emery","year":"2013","journal-title":"Br. J. Haematol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1128\/CVI.00385-08","article-title":"Incidence of Cytomegalovirus Infection in Shanghai, China","volume":"16","author":"Fang","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.773394","article-title":"Preemptive Immunotherapy for Minimal Residual Disease in Patients With T(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation","volume":"11","author":"Fan","year":"2021","journal-title":"Front. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e465","DOI":"10.3324\/haematol.2016.149880","article-title":"Cytomegalovirus Viremia, Disease, and Impact on Relapse in T-Cell Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide","volume":"101","author":"Goldsmith","year":"2016","journal-title":"Haematologica"},{"key":"B14","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of Failure Probabilities in the Presence of Competing Risks: New Representations of Old Estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1182\/blood-2013-02-487074","article-title":"CMV Reactivation After Allogeneic HCT and Relapse Risk: Evidence for Early Protection in Acute Myeloid Leukemia","volume":"122","author":"Green","year":"2013","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.medcli.2019.07.027","article-title":"Study of Cytomegalovirus Resistance in Allogeneic Hematopoietic Cell Transplant Recipients","volume":"154","author":"Guiu","year":"2020","journal-title":"Med. Clin. (Barc)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.3233\/IFS-162150","article-title":"Logistic Discrimination Based on G-Mean and F-Measure for Imbalanced Problem","volume":"31","author":"Guo","year":"2016","journal-title":"J. Intell. Fuzzy Syst."},{"key":"B18","first-page":"1157","article-title":"An Introduction to Variable and Feature Selection","volume":"3","author":"Guyon","year":"2003","journal-title":"J. Mach. Learn. Res."},{"key":"B19","volume-title":"Data Mining: Concepts and Techniques","author":"Han","year":"2011"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, Multicenter Standardization of Acute Graft-Versus-Host Disease Clinical Data Collection: A Report From the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B21","article-title":"The Elements of Statistical Learning: Data Mining, Inference, and Prediction","author":"Hastie","year":"2009"},{"key":"B22","volume-title":"Applied Logistic Regression","author":"Hosmer","year":"1989"},{"key":"B23","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s11684-019-0681-0","article-title":"Positive Stool Culture Could Predict the Clinical Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation","volume":"13","author":"Hu","year":"2019","journal-title":"Front. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/bmt.2013.49","article-title":"CMV Reactivation Is Associated With a Lower Incidence of Relapse After Allo-SCT for CML","volume":"48","author":"Ito","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"B25","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B26","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/bjh.12875","article-title":"Relationship Between Cytomegalovirus (CMV) Reactivation, CMV-Driven Immunity, Overall Immune Recovery and Graft-Versus-Leukaemia Effect in Children","volume":"166","author":"Jeljeli","year":"2014","journal-title":"Br. J. Haematol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s00277-015-2446-4","article-title":"Early Detection of Cytomegalovirus-Specific Cytotoxic T Lymphocytes Against Cytomegalovirus Antigenemia in Human Leukocyte Antigen Haploidentical Hematopoietic Stem Cell Transplantation","volume":"94","author":"Kato","year":"2015","journal-title":"Ann. Hematol."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.06.009","article-title":"Patients With Refractory Cytomegalovirus (CMV) Infection Following Allogeneic Haematopoietic Stem Cell Transplantation Are at High Risk for CMV Disease and Non-Relapse Mortality","volume":"21","author":"Liu","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"B29","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/ajh.25839","article-title":"Prognostic Factors and Long-Term Follow-Up of Basiliximab for Steroid-Refractory Acute Graft-Versus-Host Disease: Updated Experience From a Large-Scale Study","volume":"95","author":"Liu","year":"2020","journal-title":"Am. J. Hematol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the Management of Cytomegalovirus Infection in Patients With Haematological Malignancies and After Stem Cell Transplantation From the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.hoc.2010.11.011","article-title":"Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients","volume":"25","author":"Ljungman","year":"2011","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1182\/blood-2005-05-2146","article-title":"Conditioning Including Antithymocyte Globulin Followed by Unmanipulated HLA-Mismatched\/Haploidentical Blood and Marrow Transplantation Can Achieve Comparable Outcomes With HLA-Identical Sibling Transplantation","volume":"107","author":"Lu","year":"2006","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.bbmt.2010.02.007","article-title":"Protective Immunity Transferred by Infusion of Cytomegalovirus-Specific CD8(+) T Cells Within Donor Grafts: Its Associations With Cytomegalovirus Reactivation Following Unmanipulated Allogeneic Hematopoietic Stem Cell Transplantation","volume":"16","author":"Luo","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1086\/504811","article-title":"Infectious Complications Associated With Alemtuzumab Use for Lymphoproliferative Disorders","volume":"43","author":"Martin","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"B36","first-page":"1075","article-title":"Severe Infections After Allogeneic Peripheral Blood Stem Cell Transplantation: A Matched-Pair Comparison of Unmanipulated and CD34+ Cell-Selected Transplantation","volume":"86","author":"Martino","year":"2001","journal-title":"Haematologica"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl. J. Med."},{"key":"B38","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1182\/blood.V67.4.1162.1162","article-title":"Cytomegalovirus Infection After Bone Marrow Transplantation: An Association With Acute Graft-V-Host Disease","volume":"67","author":"Miller","year":"1986","journal-title":"Blood"},{"key":"B39","volume-title":"The Discipline of Machine Learning, Carnegie Mellon University, School of Computer Science","author":"Mitchell","year":"2006"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26475","article-title":"Basiliximab for Steroid-Refractory Acute Graft-Versus-Host Disease: A Real-World Analysis","author":"Mo","year":"2022","journal-title":"Am. J. Hematol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/ajh.23443","article-title":"The Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) Is an Outcome Predictor for Partially Matched Related Donor Transplantation","volume":"88","author":"Mo","year":"2013","journal-title":"Am. J. Hematol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/tid.12553","article-title":"Late-Onset Severe Pneumonia After Allogeneic Hematopoietic Stem Cell Transplantation: Prognostic Factors and Treatments","volume":"18","author":"Mo","year":"2016","journal-title":"Transpl Infect. Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.eng.2020.12.005","article-title":"Disease Risk Comorbidity Index for Patients Receiving Haploidentical Allogeneic Hematopoietic Transplantation","volume":"7","author":"Mo","year":"2021","journal-title":"Engineering"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.scib.2018.08.008","article-title":"The Role of Collateral Related Donors in Haploidentical Hematopoietic Stem Cell Transplantation","volume":"63","author":"Mo","year":"2018","journal-title":"Sci. Bull."},{"key":"B45","doi-asserted-by":"publisher","first-page":"370","DOI":"10.2307\/2344614","article-title":"Generalized Linear Models","volume":"135","author":"Nelder","year":"1972","journal-title":"J. R. Stat. Society: Ser. A (General)"},{"key":"B46","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/CCM.0000000000002936","article-title":"An Interpretable Machine Learning Model for Accurate Prediction of Sepsis in the ICU","volume":"46","author":"Nemati","year":"2018","journal-title":"Crit. Care Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1182\/blood.V97.4.867","article-title":"Rising Pp65 Antigenemia During Preemptive Anticytomegalovirus Therapy After Allogeneic Hematopoietic Stem Cell Transplantation: Risk Factors, Correlation With DNA Load, and Outcomes","volume":"97","author":"Nichols","year":"2001","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1399-3062.2009.00414.x","article-title":"Infectious Complications Associated With Alemtuzumab Use for Allogeneic Hematopoietic Stem Cell Transplantation: Comparison With Anti-Thymocyte Globulin","volume":"11","author":"Park","year":"2009","journal-title":"Transpl Infect. Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/s41409-021-01227-8","article-title":"Hematopoietic Cell Transplantation and Cellular Therapy Survey of the EBMT: Monitoring of Activities and Trends Over 30 Years","volume":"56","author":"Passweg","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"B50","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41409-018-0380-5","article-title":"Effect of Bone Marrow CD34+cells and T-Cell Subsets on Clinical Outcomes After Myeloablative Allogeneic Hematopoietic Cell Transplantation","volume":"54","author":"Patel","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"B51","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41746-018-0029-1","article-title":"Scalable and Accurate Deep Learning With Electronic Health Records","volume":"1","author":"Rajkomar","year":"2018","journal-title":"NPJ Digit Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"61","DOI":"10.25080\/Majora-92bf1922-011","article-title":"Statsmodels: Econometric and Statistical Modeling With Python","author":"Seabold","year":"2010","journal-title":"Proc. 9th Python Sci. Conf."},{"key":"B53","doi-asserted-by":"publisher","first-page":"20406207211072838","DOI":"10.1177\/20406207211072838","article-title":"Efficacy and Safety of Mesenchymal Stem Cells Treatment for Multidrug-Resistant Graft-Versus-Host Disease After Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation","volume":"13","author":"Shen","year":"2022","journal-title":"Ther. Adv. Hematol."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.749266","article-title":"Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-Versus-Host Disease","volume":"12","author":"Shen","year":"2021","journal-title":"Front. Immunol."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.757002","article-title":"Preemptive Interferon-\u03b1 Therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Results of Two Registry Studies","volume":"13","author":"Shen","year":"2022","journal-title":"Front. Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s00277-015-2440-x","article-title":"The Incidence, Risk Factors, and Outcomes of Primary Poor Graft Function After Unmanipulated Haploidentical Stem Cell Transplantation","volume":"94","author":"Sun","year":"2015","journal-title":"Ann. Hematol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/j.bbmt.2015.07.019","article-title":"Cytomegalovirus Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation Is Associated With a Reduced Risk of Relapse in Patients With Acute Myeloid Leukemia Who Survived to Day 100 After Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-Related Complication Working Group","volume":"21","author":"Takenaka","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early Cytomegalovirus Reactivation Remains Associated With Increased Transplant-Related Mortality in the Current Era: A CIBMTR Analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jcyt.2020.01.007","article-title":"Bone Marrow Haploidentical Transplant With Post-Transplantation Cyclophosphamide: Does Graft Cell Content Have an Impact on Main Clinical Outcomes","volume":"22","author":"Teofili","year":"2020","journal-title":"Cytotherapy"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for Preventing Infectious Complications Among Hematopoietic Cell Transplantation Recipients: A Global Perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1016\/j.scib.2021.06.002","article-title":"Optimizing Antithymocyte Globulin Dosing in Haploidentical Hematopoietic Cell Transplantation: Long-Term Follow-Up of a Multicenter, Randomized Controlled Trial","volume":"66","author":"Wang","year":"2021","journal-title":"Sci. Bull."},{"key":"B62","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1182\/blood-2015-02-627786","article-title":"Haploidentical vs Identical-Sibling Transplant for AML in Remission: A Multicenter, Prospective Study","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-019-0781-y","article-title":"Low-Dose Post-Transplant Cyclophosphamide and Anti-Thymocyte Globulin as an Effective Strategy for GVHD Prevention in Haploidentical Patients","volume":"12","author":"Wang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13045-018-0564-x","article-title":"The Consensus on Indications, Conditioning Regimen, and Donor Selection of Allogeneic Hematopoietic Cell Transplantation for Hematological Diseases in China-Recommendations From the Chinese Society of Hematology","volume":"11","author":"Xu","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41409-021-01431-6","article-title":"Hematopoietic Stem Cell Transplantation Activity in China 2019: A Report From the Chinese Blood and Marrow Transplantation Registry Group","author":"Xu","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"B66","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/bmt.2015.306","article-title":"Causes of Mortality After Haploidentical Hematopoietic Stem Cell Transplantation and the Comparison With HLA-Identical Sibling Hematopoietic Stem Cell Transplantation","volume":"51","author":"Yan","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"B67","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/9781118416426.ch87","article-title":"Cytomegalovirus Infection","volume-title":"Thomas\u2019 Hematopoietic Cell Transplantation: Stem Cell Transplantation","author":"Zaia","year":"2016"},{"key":"B68","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13045-021-01159-2","article-title":"The Consensus From The Chinese Society of Hematology on Indications, Conditioning Regimens and Donor Selection for Allogeneic Hematopoietic Stem Cell Transplantation: 2021 Update","volume":"14","author":"Zhang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00277-020-04273-2","article-title":"Ruxolitinib Is an Effective Salvage Treatment for Multidrug-Resistant Graft-Versus-Host Disease After Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation Without Posttransplant Cyclophosphamide","volume":"100","author":"Zhao","year":"2021","journal-title":"Ann. Hematol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1093\/cid\/ciz368","article-title":"First-Line Therapy With Donor-Derived Human Cytomegalovirus (HCMV)-Specific T Cells Reduces Persistent HCMV Infection by Promoting Antiviral Immunity After Allogenic Stem Cell Transplantation","volume":"70","author":"Zhao","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B71","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41746-020-00372-6","article-title":"Machine Learning-Based Prediction of COVID-19 Diagnosis Based on Symptoms","volume":"4","author":"Zoabi","year":"2021","journal-title":"NPJ Digit Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/clinchem\/39.4.561","article-title":"Receiver-Operating Characteristic (ROC) Plots: A Fundamental Evaluation Tool in Clinical Medicine","volume":"39","author":"Zweig","year":"1993","journal-title":"Clin. Chem."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.862526\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T16:21:01Z","timestamp":1648484461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.862526\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,22]]},"references-count":72,"alternative-id":["10.3389\/fcimb.2022.862526"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2022.862526","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,22]]},"article-number":"862526"}}